SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Business partners shaking hands after closing a deal
Mergers & acquisitions
Crown Laboratories to Buy Botox Rival Revance Therapeutics for $924M
The acquisition announced Monday will give Crown access to Revance’s Daxxify, a competitor to AbbVie’s Botox, which is indicated for frown lines and for cervical dystonia.
August 13, 2024
 · 
2 min read
 · 
Tristan Manalac
Rajesh Misra, Principal, Life Sciences Quality and Regulatory, KPMG; Denise Mead, Healthcare and Life Sciences Technology Leader, Microsoft; Don Soong, Sr. Director/GM, QARA and Spend Transparency Solutions, IQVIA
Partnered
QARA Professionals Question a Future with Cybersecurity Issues, US Litigation, and the EU AI Act
At a private event held amid the fallout from the CrowdStrike incident, cybersecurity issues took a front seat, with the consequences of the evolving EU AI Act and the Loper Bright and Corner Post decisions also raising concerns for quality assurance and regulatory affairs professionals.
August 12, 2024
 · 
8 min read
 · 
BioSpace Insights
Pictured: Entrance to Pfizer's office in Belgium
RSV
Pfizer Nabs Pivotal Phase III Win for RSV Vaccine in Immunocompromised Adults
Pfizer on Monday reported a “strong neutralizing response” against both subtypes of respiratory syncytial virus across all cohorts and age groups, according to topline data.
August 12, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Photo illustration of hundred dollar bill and graph
Startups
Halda Therapeutics Raises $126M in Series B Extension to Advance Two Cancer Candidates
The Connecticut-based biotech, which emerged from stealth last year, has secured $202 million to date as it looks to move two assets targeting prostate and breast cancer into the clinic.
August 12, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Sign at FibroGen's headquarters in Calif
Layoffs
FibroGen to Lay Off 127 Workers in San Francisco
FibroGen expects its headcount reduction, which is tied to eliminating 75% of its U.S. workforce, to be mostly complete by the end of the first quarter of 2025.
August 12, 2024
 · 
1 min read
 · 
Angela Gabriel
3D illustration of the thyroid gland with nodules inside human body
Rare diseases
Ascendis’ Hypoparathyrodism Drug Secures FDA Approval Following Tough Regulatory Path
Ascendis Pharma’s palopegteriparatide was previously rejected by the regulator due to manufacturing problems, and the review period for its resubmitted application was extended by three months.
August 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Illistration of a broken head figure to symbolize psychological stress
Psychedelics
MDMA Papers Retracted for ‘Unethical Conduct’ on Heels of Lykos’ FDA Rejection
A day after the regulator denied approval of Lykos’ MDMA-assisted PTSD therapy, a medical journal pulled three studies related to the use of the psychedelic in the indication.
August 12, 2024
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
Regulatory
FDA Needs More Time to Review Humacyte’s Blood Vessel Implant
Humacyte’s stock price dropped 18% in after-hours trading Friday after the company announced the FDA requires additional time to review its Biologic License Application. No reason was given for the delay or an updated decision date.
August 12, 2024
 · 
1 min read
 · 
Tristan Manalac
Hand holding a nasal spray bottle against a white background
Approvals
ARS Pharma Gets FDA Green Light for First Nasal Spray for Severe Allergic Reactions
ARS Pharma’s neffy on Friday became the first FDA-approved nasal spray to address severe allergic reactions, including those that might lead to life-threatening anaphylaxis.
August 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS